Results 251 to 260 of about 789,557 (313)

α-Glucosidase Inhibitory Potential of <i>Citrus reticulata</i> Peel-Derived Flavonoids-A Prelude for the Management of Type 2 Diabetes. [PDF]

Food Sci Nutr
Baloyi IT, Rabbad AH, Gama NH, Malgas S.
europepmc   +1 more source

The Diagnostic Odyssey of a Biochemically Confirmed Case of ML II: The First Western Patient With LYSET Deficiency

Clinical Genetics, Volume 110, Issue 1, Page 125-130, July 2026.
We identify a female patient with a homozygous nonsense variant (p.Gln38Ter) in the LYSET gene. This is the first western report of a challenging case of an extensive diagnostic odyssey and demonstrates that the LYSET gene must be considered in the differential diagnosis when M6P‐labeled lysosomal enzymes are altered.
Fernanda Sperb‐Ludwig, Taciane Alegra, Leonardo Martinello da Rosa, Nataniel Floriano Ludwig, Renata Voltolini Velho, Ida Vanessa Doederlein Schwartz   +5 more
wiley   +1 more source

Polyphenols of <i>Zingiber roseum</i> Leaf as a Potential Source of α‑Glucosidase Inhibitors for Type‑2 Diabetes Management: LC-MS/MS, Pharmacological and Computational Analysis. [PDF]

ACS Omega
Sakib MS, Eruygur N, Ahmed S, Yilmaz MA, Mannan Siam SM, Moniruzzaman M, Naim Uddin SM, Tarhan A, Rahman MN, Shahid Ud Daula AFM.   +9 more
europepmc   +1 more source

Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real‐world experience

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Aims Fixed‐ratio combinations such as iGlarLixi are recommended over premixed insulin as first‐line injectable therapy for type 2 diabetes mellitus (T2DM), yet real‐world evidence on transitions from premix to iGlarLixi remains limited. This study aimed to evaluate the efficacy and safety of switching from premixed insulin to iGlarLixi in a ...
Chun‐Jui Huang, Shun‐Jie Yang, Cheng‐Pin Cheng, Chun‐Hsing Lin, Ya‐Chun Lee, Harn‐Shen Chen   +5 more
wiley   +1 more source

Safety evaluation of an extension of use of the food enzyme glucan 1,4-α-glucosidase from the genetically modified <i>Aspergillus niger</i> strain NZYM-BF. [PDF]

EFSA J
EFSA Panel on Food Enzymes (FEZ), Zorn H, Barat Baviera JM, Bolognesi C, Catania F, Gadermaier G, Greiner R, Mayo B, Mortensen A, Roos YH, Solano MLM, Van Loveren H, Vernis L, Manghi A, Cavanna D, Liu Y.   +15 more
europepmc   +1 more source

A systematic review and meta‐analysis of the relative benefit of dual versus single oral hypoglycaemic therapy following diagnosis with type 2 diabetes (T2D)

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Introduction Achieving and sustaining target glycated haemoglobin (HbA1c) levels is fundamental in the management of type 2 diabetes (T2D). We here aimed to assess whether initial dual oral therapy outperforms monotherapy in reaching glycaemic targets in patients with treatment‐naive or early‐stage T2D.
Mairead Kelly, Sushant Saluja, Hugh Logan Ellis, Sarah Jamil, Martin B. Whyte, Adrian Heald   +5 more
wiley   +1 more source

A Novel Peptide Derived from Sea Buckthorn Leaves: Enzymatic Preparation, Dual Inhibitory Activity Against α-Glucosidase and DPP-IV, and Its Molecular Mechanism. [PDF]

Foods
Qin X, Peng Y, Huang Y, Wang F, Guo J.
europepmc   +1 more source

Impact of Simulated Risk Factor Management on Cardiovascular Disease and Costs in Type 2 Diabetes Using the ABC Model

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5670-5683, July 2026.
ABSTRACT Aims We evaluated the impact of scenario‐based multifactorial control on the 3‐year incidence of fatal/non‐fatal cardiovascular disease (CVD) and associated healthcare costs in Asian patients with type 2 diabetes (T2D). Materials and Methods We applied the validated ‘ABC’ model to simulate the 3‐year impact of attaining multiple treatment ...
Lee‐Ling Lim, Eric S. H. Lau, Juliana N. M. Lui, Linong Ji, A. G. Unnikrishnan, Sirinart Sirinvaravong, Siew‐Pheng Chan, Soo Lim, Andrea O. Y. Luk, Juliana C. N. Chan   +9 more
wiley   +1 more source

An innovative strategy coupling cluster fraction with ultrafiltration UPLC-QTOF-MS/MS for screening α-glucosidase inhibitors from barley seedlings. [PDF]

Food Chem X
Lin C, Luo J, Wang S, Shen C, Zhang S, Liu Y, Song Z, Ma Y, Chen T, Li Y.   +9 more
europepmc   +1 more source

Bifidobacterium bifidum G9‐1 Intake Improves Gastrointestinal Symptoms in Type 2 Diabetes Mellitus: An Open‐Label, Randomized Controlled Trial (Binary STAR Study)

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5952-5967, July 2026.
ABSTRACT Aims To evaluate the effects of probiotics Bifidobacterium bifidum G9‐1 (BBG9‐1) on gastrointestinal symptoms in patients with Type 2 diabetes mellitus (T2DM) with diarrhoea or constipation. Materials and Methods In a 12‐week open‐label randomised controlled trial, 100 participants were randomized 1:1 to a control or BBG9‐1 group, with 12 mg ...
Genki Kobayashi, Yoshitaka Hashimoto, Tomoyuki Matsuyama, Noriyuki Kitagawa, Saori Majima, Takafumi Senmaru, Emi Ushigome, Hiroshi Okada, Naoko Nakanishi, Masahide Hamaguchi, Michiaki Fukui   +10 more
wiley   +1 more source